Amgen stock faces ACR data test with dazodalibep results

Published on 11/10/2026 at 16:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock approaches a key autoimmune-data presentation on Wednesday. The OASIZ-301 study covers approximately 621 patients with Sjogren's disease.

Amgen's Next Clinical Milestone

Amgen will present late-breaking OASIZ-301 results at ACR Convergence on Wednesday, November 11.
The study targets systemic disease activity and patient-reported dryness in Sjogren's disease.
OASIZ-303 remains a separate Phase 3 study expected to complete in the fourth quarter of 2026.

Amgen, US0311621009, Illustration mit AI erstellt.

Amgen is approaching a key autoimmune-pipeline event as it prepares to present detailed Phase 3 data for dazodalibep at the American College of Rheumatology Convergence on Wednesday, November 11. A release published by Amgen adds that the OASIZ-301 trial enrolled approximately 621 participants and evaluates dazodalibep, a CD40L antagonist.

What Investors Will Watch

The late-breaking oral presentation is scheduled for 8:45 a.m. Eastern Time. It covers adults with Sjogren's disease and moderate-to-severe systemic disease activity, giving investors a scheduled readout on a potential addition to Amgen's autoimmune portfolio.

Amgen said OASIZ-301 met its primary endpoint. At Week 48, the least-squares mean ESSDAI score change was minus 5.6 points with 1,500 milligrams every four weeks and minus 5.2 points with 3,000 milligrams every 12 weeks, compared with minus 3.8 points for placebo. The placebo-adjusted differences were 1.8 and 1.4 points, respectively.

The four-week regimen also improved patient-reported dryness on the ESSPRI and DASPRI measures. Treatment-emergent adverse events, serious adverse events and discontinuations occurred at similar rates across the study groups, according to the company release. The findings remain preliminary and investigative, and dazodalibep is not approved for this use.

Pipeline Milestones Remain Ahead

Amgen expects the separate OASIZ-303 Phase 3 study, which evaluates patients with high symptom burden and low systemic disease activity, to complete in the fourth quarter of 2026. OASIZ-304 is assessing long-term safety and tolerability in eligible participants from OASIZ-301 and OASIZ-303.

Amgen stock traded at 413.20 euros on Lang & Schwarz at 16:02 CET on Tuesday, November 10, 2026, 0.08 percent below the Xetra close of Monday, November 9. The quote was below the previous report's 416.13-euro level at 13:31 CET on Tuesday, November 10.